Table 2.

Effect of dietary supplementation on metabolic variables and risk factors, data shown as change from baseline at week 8^† (Mean values with their standard errors)

	Placebo			EGCG
	n	Least square mean	SE	n	Least square mean	SE
Insulin sensitivity
Fasting insulin (mU/l)	42	−0·16	0·54	46	−0·088	0·52
HOMAIR	42	0·011	0·14	46	0·011	0·14
OGTTISI	28	4·05	4·61	34	4·83	4·18
Insulin secretion
HOMA%B	42	−5·55	5·94	46	−3·86	5·67
OGTTInsulinogenic index	36	10·03	4·15	38	1·76	4·04
Glucose tolerance
Fasting glucose (mmol/l)	42	0·051	0·049	46	0·057	0·047
OGTT2 h glucose (mmol/l)	40	−0·029	0·16	45	−0·28	0·15
OGTTTotalAUCglucose (mmol h/l)	28	−0·86	0·31	34	−0·35	0·28
HbA1c (%)	42	0·099	0·053	43	0·029	0·053
Metabolic risk factors
BMI (kg/m2)	42	0·058	0·076	46	−0·0042	0·072
Waist circumference (cm)	42	−0·39	0·46	46	−0·74	0·44
Body fat (%)	41	−0·0021	0·14	46	−0·050	0·13
Systolic blood pressure (mmHg)	42	−0·26	1·11	46	−2·85	1·06
Diastolic blood pressure (mmHg)	42	−0·058	0·75	46	−2·68*	0·72
Total cholesterol (mmol/l)	42	0·09	0·11	46	0·086	0·10
HDL-cholesterol (mmol/l)	42	0·031	0·023	46	−0·0062	0·022
LDL-cholesterol (mmol/l)	42	−0·12	0·087	46	0·012	0·083
TAG (mmol/l)	42	−0·095	0·13	46	0·19	0·12

EGCG, epigallocatechin-3-gallate; HOMA_IR, homeostasis model assessment of insulin resistance; HOMA_%B, homeostasis model assessment of pancreatic β-cell function; OGTT, oral glucose tolerance test.

Value was significantly different from that of the placebo:

^*P≤0·05 (mixed model analysis of covariance, baseline as a covariate, subject as a random effect and treatment group as a fixed effect).

^†For details of subjects and procedures, see Table 1 and Subjects and methods section.